The four kinds of oligopeptides specific in amino acid sequence to a tat dopamine transporter (DAT), peptide-1-peptide-4, were chemically synthethized. An attempt to produce antipeptide antibodies against these oligopeptides was made with an in vitro immunization method. Two monoclonal antibodies, MAbs H-la and H-lb, were produced against one of the oligopeptides, peptide-1. Western blot analysis confirmed that the two antibodies recognized a *85,000 Da protein in a synaptosomal ftaction prepared from the tat striatum but none in the fraction from the cerebellum. The specificity of the antibody to DAT was also confirmed by an antibody absorption test using two synthetic oligopeptides, one of which is specific only to DAT. These results have confirmed the specificity of the present antibody to DAT. Th> expression and subcellla localization of DAT were immunohistochemically examined with MAbs H-la and H-lb in PC12 cells treated with nerve growth factor (NGF). The antibody labeled the surface of PC12 cells. When the cells were treated with NGF, the expression of DAT was
Introduction
Catecholaminergic nerve terminals have a Na+-dependent transporter system to take up catecholamines previously released into the synaptic cleft (25,35). For many catecholaminergic synapses, this uptake process is a major means for reducing transmitter concentration in the synaptic cleft and thereby terminating the postsynaptic response. The dopamine transporter (DAT) belongs to the Na+dependent transporter family (44). This transporter may be the site at which cocaine and related drugs exert their reinforcing properties (2,24,37), and has been suggested to be a principal cocaine receptor (15,28,29). The binding site for cocaine is crucial for the ' Supported in part by a grant from the Ministry of Education, Science, Correspondence to: Tomoko Kadota, Dept. of Anatomy, Chiba Univ. and Culture of Japan (TK).
Medical School, Chiba 260, Japan. significantly emphasized, first in the area mainly including the Golgi apparatus and rough endoplasmic reticulum and then on the surface of growth cones from the beginning of neurite outgrowth. DATwas detected by Western blot analysis in a microsomal fraction prepared from PC12 cells. The activity of DAT in the PC12 cells was pharmacologically confirmed by the uptake of [3H]-dopamine and blockade by uptake inhibitors. The NGF treatment doubled the dopamine uptake activity. GBRl2909, a specific inhibitor of DAT, blocked the [3H]-dopamine at a concentration of lo-' M.
The expression of DAT and norepinephrine transporter (NET) mRNA in the PC12 cells was d e d by merse transcriptase-polymerase chain reaction (RT-PCR). DAT mRNA significantly increased in the NGF-treated cells after 7 days of incubation, whereas NET mRNA markedly decreased. action of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP), a selective neurotoxin that produces Parkinsonism (26). Recently, cDNA cloning studies have elucidated the primary structures of DAT and other homologous members of the Na'-dependent neurotransmitter transporter family that are expressed in rat and human brain and in canine kidney (3,9,20,22,28,33,41,42,45+48) . Two groups have cloned the cDNA of rat DAT which encoded a protein of 611) amino acids (69 KD) with four putative N-linked glycosylation sites in a large extracellular loop and three potential protein kinase C phosphorylation sites (28,41). Moreover, two cocaine binding sites were conferred from a single cDNA, suggesting that a single transporter species codes for both low-and high-affinity binding sites (5.24).
Dopamine uptake is related to locomotor activity, hormone release, disorders such as Parkinson disease and schizophrenia. positive reinforcement, and cocaine self-administration (37.47). In spite of the physiological, pathological, and pharmacological importance 989 330 KADOTA, YAMAAI, SAITO, AKITA, KAWASHIMA, MOROI, INAGAKI, KADOTA of this system, little is known about the morphological details of this transporter during development.
We have produced monoclonal antibodies (MAbs) against oligopeptides of a DAT protein. Using the antipeptide antibody, we have examined the expression of DAT in the neuron, especially the changes in subcellular localization of DAT during development. In this study we used PC12 cells as a neuronal system for the experiments (21). PC12 cells are a clonal line of rat pheochromocytoma cells that secrete acetylcholine and catecholamines and develop as neuron-like cells after treatment with nerve growth factor (NGF) (19) . Moreover, this cell line has the capacity to take up and accumulate norepinephrine and dopamine by a Na'-dependent transporter-mediated process (18,30,36). The h-clone used in the present study is a subclonal cell line of PC12 cells that secrete mainly dopamine.
Materials and Methods
Drugs and Chemicals. Chemicals were purchased from Nacalai-Tesque (Kyoto, Japan) and Amersham-Japan (Tokyo, Japan). Cocaine and methamphetamine were obtained from Takeda Chemical Industries (Osaka, Japan) and Dai-Nippon Pharmaceuticals (Tokyo, Japan), respectively. GBR-12909 was obtained from Research Biochemicals (Natick, MA). Fluorescenceconjugated second antibodies were purchased from Medical Biological Laboratory (Tokyo. Japan) and Funakoshi Pharmaceuticals (Tokyo, Japan).
Production of Monoclonal Antibodies. Four oligopeptide probes, based on an amino acid sequence deduced from rat DAT cDNA cloning (41) , were used to produce the antibodies. Amino acid sequences of 217-232, 374-387. 1-7, and 11-19 of DAT were designed as peptide-1, -2, -3, and -4, respectively, and were chemically synthesized using a Beckman synthesizer by the team of Dr. H. Tashiro of Fujiya Bioscience Laboratory (Tokyo, l apan) ( Figure 1A ). These peptides were located in the second and fourth extracellular loops and at the N-terminal of DAT Clones of the MAbs against each peptide were prepared by an in vitro immunization method according to Boss (6). using PA1 myeloma cells.
The specificity of the antibodies against the DAT oligopeptides was determined by ELISA. The immunoglobulin subclasses of the obtained MAbs were determined with an MAb typing kit for mouse or rat culture supernatants (Binding Site; Birmingham, UK). The specificity of these MAbs to DAT was examined by Western blotting. A synaptosomal fraction (P2) was prepared from the striatum and cerebellar cortex of rat (Wistar strain) (27) , subjected to polyacrylamide gel electrophoresis, blotted onto a nitrocellulose membrane, and probed with the antibodies. The striatum was used as material specific to DAT and the cerebellum to NET.
The anterior half of the peptide-l of DAT had the same amino acid sequence as a part of the rat norepinephrine transporter (NET) (41) , but the posterior half was specific for DAT ( Figure 1B) . To characterize the MAb against peptide-1, two oligopeptides, H-04 and H-11, were used for absorption test, The former is the same as the anterior half of peptide-1 and is common to DAT and NET in amino acid sequence. The latter is the same as the posterior half of peptide-l and is specific to DAT ( Figure 1B ). The mixture of the antibody and the oligopeptide, H-04 and H-11, was applied to a nitrocellulose membrane for Western blotting.
Immunohistochemistry. PC12 cells, clone h (21). were routinely grown in a medium containing 90% Dulbecco's modified Eagle's medium, 5% newborn calf serum, and 5 % heat-inactivated horse serum in plastic tissue flasks at 37°C in a humidified 10% CO2 incubator. After being grown in this medium, the cells were plated at 2 x lo4 cells/cm2 onto collagencoated plates and then incubated in N2 medium with or without NGF (40 nglml) for predetermined periods (39) . The N2 medium was composed of a 1:1 mixture of Ham's F12 medium and the Dulbecc+Vogt modifica-A Extracellular space
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* * * * * * * * * * * * tion of Eagle's medium supplemented with 5 % (v/v) horse serum, 2.5% HEPES buffer, and 40 mM penicillin, 8 pg/ml of ampicillin, and 90 pg/ml of streptomycin, 5 pglml of insulin, 100 Bg/ml of transferrin, 20 nM progesterone, 100 pg/mM putrescine, and 30 nM selenium (as Na2SeO3) (7). After addition of NGF (40 nglml), the cells were incubated for 1-7 days (39) . Some cells were not treated with NGF as a control. After incubation the cells were fixed with a mixture of 4% paraformaldehyde, 0.1% glutaraldehyde, and 0.25% ethylacetimidate in 0.1 M phosphate buffer, pH 7.4, for 2 hr. After fixation, the cells were initially incubated with 0.1% Triton X-100 in PBS for membrane permeabilization. Subsequently, the materials were rinsed three times with PBS. blocked with 3% bovine serum albumin and 10% normal goat serum in PBS for 30 min, and then incubated with the MAb for 16 hr at 4'C. After rinsing, the cells were incubated with a second antibody, FIE-conjugated anti-mouse IgM, for 4 hr and were rinsed three times in PBS. The materials were examined with a confocal laser microscope MRC-600 (Bio-Rad Laboratories-Japan; Tokyo, Japan).
Detection of DAT in Subcellular Fractions. PC12h cells cultured with NGF for 7 days were harvested ahd homogenized, from which two kinds of subcellular fractions, microsomal and supernatant. were prepared by a conventional fractionation procedure (27) . The specimens were subjected to PAGE and analyzed hy Western hlotting. using MAh H-la o r ti-lb.
[3H]-Dopamine Uptake Experiments. The uptake experiments were carried out according to Giroser al. (IS). After incubation in the N2 medium with or without NGF for 2 days, the cells were incubated in the uptake buffer containing 5 mM Tris-base, 7.5 mM HEPES. 140 mM NaCI. 5.4 mM KCI. 1.8 mM CaC12. 0.8 mM MgSO.1. 1 mM ascorbic acid. and 5 mM D-glucose at a final pH of 7.1. Then the cells were incubated with I5 nM ['HI-dopamine in the uptake buffer for 3-30 min at 30°C. At the end of incubation. the cells were placed on ice, washed four times with cold PBS. and then resuspended in 0.6 ml of 0.1 N NaOH. An aliquot was then taken for scintillation counting. For determination of uptake inhibition. the cells were incubated with the uptake inhibitor. cocaine. GBR12909. or methamphetamine at a concentration of lo-.' to lo-"' M and 50 nM of [3H]dopamine in a final volume of 1 ml for 30 min at 37'C. After incubation the cells were treated as mentioned above for scintillation counting. Specific uptake was determined with the difference between the total and nonspecific uptake in the absence or presence of 1000-fold unlabeled dopamine.
Expression of DAT mRNA in PC12h Cells. To confirm the presence of DAT in PC12h cells, the expression of DAT mRNA was examined by RT-PCR. Total RNA was isolated from the PC12h cells treated or untreated with NGF by the guanidium thiocyanate-cesium chloride method (10). and first-strand cDNA was synthesized by a method previously described (16). cDNA derived from 160 ng total RNA wascombined with 0.1 VM oligonucleotide primers specific to the nucleotide sequences of rat DAT, rat NET, and rat 8-actin in 100 NI of a solution containing 50 mM KCI. 10 mM Tris-HCI (pH 8.3). 1.5 mM MgC12. and 200 pM of each dNTP (38) ( Table 1) . and PCR reactions were carried out in a DNA thermal cycler (Perkin Elmer Cetus; Norwalk, CT). After an initial denaturation at 94'C for 3 min. the samples were subjected to 40 cycles of amplification under the following conditions: annealing at 58°C for 1 min. extension at 72'C for 1 min. and denaturation at 94'C for 1 min. The PCR products were analyzed by electrophoresis on 2% agarose gels. Primer pairs for amplifying rat DAT, rat NET, and 8-actin cDNAs were prepared as shown in Table 1 . PActin cDNA was amplified as a control (32). The sizes of the PCR products are 305 RP for DAT, 242 R P for NET, and 287 BP for 8-actin.
Results

Cbaructeri'ution of the Monoclonal Antibodies
The two antibodies against peptide-1 of DAT, MAb H-la and H-lb. recognized a *85,000 Da protein in the P2 fraction of the striatum at a protein concentration of 50 pglml (Figure 2A) . In contrast, the MAbs did not recognize any proteins at the same pro-tein concentration range in the P2 fraction prepared from the cerebellum, which contained the norepinephrine (NE) terminals. However, the population of the NE terminals in the cerebellar cortex is not as high as that of the DA terminals in the striatum (14). Therefore, the P2 fraction in the cerebellar cortex was used at higher protein concentrations for Western blotting to confirm the specificity of the DAT antibody. The antibody did not recognize any proteins in the cerebellum, even at a very high protein concentration of 1 mglml, which was 20-fold higher than that (50 pglml) used for the striatum (Figure 2B) .
The specificity of the present antibody against peptide-1 was also examined with an absorption test using two oligopeptides, H-04 and H-11. The former is the anterior half of peptide-1 and has a common amino acid sequence with DAT and NET, while the lat- Western blot of rat brain fraction. Two areas of rat brain, striatum and cerebellar cortex. were dissected, homogenized, and fractionated to obtain a synaptosomal (Pz) fraction according to Kadota et al. (27) . The PZ fractions were subjected to polyacrylamide gel electrophoresis. blotted onto a nitrocellulose membrane, and probed with the antipeptide antibodies MAb H-la and H-lb. The membrane was treated by the AEC method. The different groups of lanes represent the PZ fractions at various concentrations of protein from the striatum (A) and cerebellar cortex (B). (A) Lanes 1. 2, 3, and 4 contain 400, 250, 150. and 50 pg of proteinlml. respectively. (6) Lanes 1.2.3, and 4 contain 400, 500, 750, and 1000 vg of proteinlml. respectively. Numbers at left are molecular weights of standard proteins. The antibodies recognized a 45.000 oa protein in the PZ fraction of the striatum, even at a low protein concentration of 50 uglml (arrow), but no proteins in the cerebellum at a high protein concentration of 1000 vglml.
ter. the posterior half of peptide-1, is specific to DAT ( Figure 1B) . The mixture ofthe antibody and peptide-1 or H-11 failed to detect the m85.000 Da protein present in the rat striatum (Figure 3) . In contrast to this, the oligopeptide H-04 failed to absorb the antibody activity of MAb H-la or H-lb. These results suggest that the present antipeptide antibody is specific to peptide H-11, a peptide specific only to DAT. The immunoglobulin subclass of these antibodies was IgM. The other antibodies against peptide-2, -3, and -4 did not clearly recognize any proteins in the striatum. The protein recognized by MAbs H-la and H-lb was slightly higher in molecular weight than 69,000 Da, which is the M W value deduced for DAT from its amino acid sequences (28, 41) .
Immunohistochemistry of PCIZh Cell5
The expression of DAT was immunohistochemically examined in PCl2h cells using the MAbs against peptide-1. Essentially similar observations were obtained with both MAb H-la and MAb H-lb. Therefore, these antibodies were equally used in the following experiments. Figure 4 shows the immunoreactivity detected in the PC12 cells. Immunoreactive spots were interspersed on the surface of the control cells untreated with NGF (Figure 4a ). When the cells were treated with NGF, the immunoreactive protein was strongly -._ expressed and its subcellular localization dramatically changed during the following incubation period (Figures 4b-4d ). After a 5-hr incubation with NGF, the expression of the protein was reinforced in one side of the juxtanuclear area, mainly including the Golgi apparatus and the rough endoplasmic reticulum (Figure 4b . arrowheads). Moreover, the antibody labeled the restricted areas of the surface membrane, which slightly protruded (Figure 4b , arrows). These protrusions appeared to coincide with the points of initial neurite outgrowth, from which newly formed neurites later extended outwards. The upper ends of the growing neurites (the growth cones) were expanded, and their surface membrane was strongly labeled with the antibody after 2 daysof incubation (Figure 4c . arrow). The immunoreactive protein was constantly expressed on the surface of growth cones during ongoing developmental stages (Figure 4d, arrows) . Some neurites exhibited small varicosities, the surface membranes of which were also labeled with the antibody. Many immunopositive spots were distributed in the cytoplasm of the cell body and neurites (Figure 4d . arrowheads).
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Subcellular Localization of DAT
Intracellular localization of DAT was biochemically examined in PC12h cells. Two kinds of subcellular fractions, microsomal and supernatant (cytoplasmic), were analyzed by Western blotting (Figure 5) . The antibody recognized a m85.000 Da protein in the microsomal fraction, but not in the cytoplasmic fraction.
[jHJ-Dopamine Uptake and Suppression by Uptake Inhibitors
To characterize DAT suggested to be expressed in PC12h cells, the capacity of the cells to take up [3H]-dopamine was pharmacologically examined. The cells, untreated or treated with NGF, were able to take up dopamine ( Figure 6A ). At 15 nM of dopamine, a plateau was reached after 20 min of incubation. The ability to take up dopamine was reinforced by NGF treatment. The NGF-treated cells exhibited a twofold increase in [ 3H]-dopamine uptake after 20 min of incubation.
The effects of inhibitors on dopamine uptake were examined in PC12h cells ( Figure 6B ). The uptake of [jHI-dopamine by the cells was markedly inhibited by 10 -' M cocaine and completely inhibited at lo-' M. GBR12909, a specific inhibitor of DAT, blocked the DA uptake at a concentration of -7 M. Methamphetamine also inhibited DA uptake at a concentration of -' M (Figure 6B) .
Expression of DAT cDNA
The levels of expression of DAT and NET mRNA were examined in NGF-treated and untreated PC12h cells by RT-PCR (Figure 7) . The expression of DAT mRNA was low in the PC12h cells untreated with NGF, whereas it was significantly increased in the cells incubated with NGF for 7 days. On the other hand, the expression of NET mRNA was detectable in the control cells untreated with NGF but was markedly depressed after incubation with NGF for 7 days. Figure 4 Immunohistochemistry of dopamine transporter (DAT) expressed in PC12h cells Cells were incubated in N2 medium for 5 hr (a b). 2 days (c). and 6 days (d) Cells in b-d were treated with NGF DAT protein was lightly expressed on the surface of the cells untreated with NGF (a) In the cells treated with NGF. DAT signilicantly increased in the area including the Golgi apparatus (arrowheads) and restricted areas of the cell surface (arrows) alter 5-hr incubation. These areas of the cell surface slightly protruded (b) The tip of the neurite extending from the cell body was strongly labeled with the antibody (arrow) after 2 days of incubaton (c) After 6 days of incubation. the neurite grawth cones were strongly labeled (arrows) Many small positively labeled spots were observed in the perinuclear cytoplasm and in the axon (arrowheads) (d) Bar -20 um
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Discussion
Characterization of the Antibodies
Wc havc synthcsizcd four oligopcptidcs bascd on the amino acid scqucncc of a rat dopaminc transportcr (DAT), which was cloned by Kilty et al. (28) and Shimada ct al. (41) . Using thcsc peptides as antigens. two monoclonal antibodics, MAb H-la and MAb H-lb. against pcptide-1, 217-232 of thc DAT amino acid scqucncc, wcrc produced by an in vitro immunization mcthod (6). Immunoblotring analysis revealed that the antibodics rcrognized a 'W35.000 Da protein in a synaptosomal fraction from thc rat striatum, even at a low protein concentration of 50 pglml. On thc other hand, the MAbs did not react with any proteins in thc ccrebcllar cortex cvcn at a high protein conccntration of 1 mglml, which was 20fold higher than that used for the striatum. The dopaminergic tcr-mina1 is diffusely distributcd. occupying 10-12% of all terminals in thc striatum (23). whcrcas it is not observed in thc ccrcbcllar cortex (14). The distribution of the noradrcncrgic (NE) terminal has been shown to be very sparse and patchy in thc ccrcbcllar cor- (4). Therefore, the cerebellar synaptosomal fraction, which has a more than threefold higher protein concentration than the striatal fraction, may serve as an appropriate specimen to examine the crossreactivity of the antibody to NET. The present findings revealed that NET in the cerebellum was not recognized by the present antibody. These observations suggested that this antibody specifically recognizes DAT in the striatum, where a high-affinity transport system for DA is present in the nerve endings of the DA neuron (1.11.17) . The protein recognized in the striatum has a slightly higher MW than the presumptive value of DAT, 69,000 Da (41) . deduced from its amino acid sequence. However, the DAT protein has four points of N-linked glycosylation on the second extracellular loop (28.41). Such glycosylations may affect the molecular mass of the protein.
In fact. Lew et al. (31) have estimated the MW of DAT at 75,000-85.000 Da. using Rainbow markers (Amersham: Poole. UK) and have shown that treatment with deglycosylation enzymes reduces the apparent MW of the protein. Moreover, Patel et al. (34) have shown that the human and rat DAT protein is between 79-90 KD in molecular mass and that deglycosylation may reduce the molecular mass of DAT. These results strongly supported the hypothesis that the -85.000 Da protein represents DAT in the synaptosomal fraction of the striatum. Recently, Vaughan et al. (46) prepared several kinds of oligopeptides based on the amino acid sequences of DAT and produced antipeptide antibodies. This group showed that the antibody against one of their oligopeptides (peptide 5) recognized the DAT protein in the striatum. Their peptide 5 was located at the C-terminal of the second extracellular loop. Our peptide-1 was also located in the second extracellular loop. These observations have suggested that the area of the second extracellular loop of the DAT protein is highly antigenic.
Cloning of a rat norepinephrine transporter (NET) has shown that its cDNA sequence is homologous at many points with that of DAT (28.33.41) . This raises the possibility that the present antipeptide antibody might recognize NETas well as DAT. However. absorption tests using short peptides have shown that the peptide H-11 with an amino acid sequence specific to DAT reacts to the antibody, whereas the peptide H-04 with an amino acid sequence common to both DAT and NET does not. Taking these findings together with the results of Western blotting of the striatum and cerebellum. it is suggested that the present antibody against peptide-1 recognizes the specific part of DAT but not of NET.
Develbpmentd Changes of DAT Protein and mRNA in PC12h C e h
Expression of DAT mRNA has been shown in the neuron of the prenatal rat brain (13, 42) . However. the expression pattern of DAT protein has not been clearly shown in developing neurons. The present study has demonstrated very early expression of the protein in PC12h cells before neurite outgrowth, and dynamic changes of intracellular localization of DAT protein during development.
Moreover, Western blot analysis confirmed that the protein was localized in the microsomal fraction but not in the cytoplasmic fraction. These results suggest that the production of DAT protein is markedly reinforced at a very early stage of differentiation and that the protein is actively transported by the membrane structures to the growth cones through the axon. The intracellular localization of DAT was very similar to that of other synaptic proteins, such as synaptophysin (8, 12, 43) or GAP43 (40) , during development of a nerve cell. Unlike these synaptic proteins, however, the DAT protein is specific to the DA neuron. Therefore, the present antipeptide antibody of DAT may be useful to detect DA neurons during development or under certain experimental conditions, such as neural transplantation.
Pharmacological examinations indicated that the capacity of the cells to incorporate [ 3H]-dopamine increased about twofold after incubation with NGF for 2 days. Dopamine uptake inhibition by GBR12909, methamphetamine, and cocaine has confirmed the presence of DAT in PC12h cells. Consistent with the pharmacological observations, morphological examinations revealed strong expression of DAT at the growth cones of PC12h cells treated with NGF.
Using RT-PCR, we found elevated levels of DAT mRNA in PC12h cells treated with NGF for 7 days. The significant increase of DAT mRNA corresponded well with the morphological results and the increase of [ 3H]-dopamine uptake in PCUh cells treated with NGF.
In contrast to this, NET appeared to develop differently from DAT in PC12h cells. Expression of NET mRNA was clearly detected by RT-PCR in the cells before N G F treatment, but it was significantly depressed after 7 days of incubation with NGF. Hatanaka's group has observed that dopamine was increasingly produced in the cell, whereas norepinephrine could not be detected in cells treated with NGF (personal communication). These findings imply a preferential synthesis of DAT in developing P C U h cells.
